Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
07:38am, Monday, 21'st Jul 2025
– Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company�
MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission
Amneal to Report Second Quarter 2025 Results on August 5, 2025
08:00am, Wednesday, 09'th Jul 2025
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Compa
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
10:40am, Monday, 30'th Jun 2025
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10:46am, Friday, 13'th Jun 2025
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
08:00am, Thursday, 12'th Jun 2025
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolo
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
11:01am, Wednesday, 04'th Jun 2025
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Amneal to Participate at Upcoming Investor Conferences in June
04:05pm, Thursday, 29'th May 2025
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5,
3 Reasons Growth Investors Will Love Amneal (AMRX)
01:46pm, Monday, 26'th May 2025
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
US FDA approves Amneal's migraine treatment
08:16am, Thursday, 15'th May 2025
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate pat
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
11:01am, Friday, 09'th May 2025
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
01:45pm, Thursday, 08'th May 2025
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
07:00am, Thursday, 08'th May 2025
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceu
